A Study YL201 in Patients With Selected Advanced Solid Tumors
NCT06057922
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
990
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumor
Interventions
DRUG:
YL201 for Injection
Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.